Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients with High-risk Stage I or Stage II Endometrial Cancer
This clinical trial is studying whether pelvic radiation therapy is more effective than vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with endometrial cancer.
Study Type: Interventional
Age/Sex Requirements: 18 years+ (female)
Sponsor: Gynecologic Oncology Group
Purpose: This clinical trial is studying whether pelvic radiation therapy is more effective than vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with endometrial cancer. The primary outcome measure of the study will be duration of recurrence-free survival, with secondary measures including duration of overall survival; incidences of vaginal, pelvic, or distant recurrence; death from endometrial cancer; toxicity; and quality of life.
